Vera Therapeutics (VERA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Key Insights
Critical company metrics and information
Share Price
$48.46Market Cap
$3.07 BillionTotal Outstanding Shares
63.32 Million SharesTotal Employees
82Dividend
No dividendIPO Date
May 14, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.veratx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $185000.00 |
Net Cash Flow | $185000.00 |
Net Cash Flow From Financing Activities, Continuing | $305.55 Million |
Net Cash Flow From Operating Activities | $-120.64 Million |
Net Cash Flow From Investing Activities | $-185.09 Million |
Net Cash Flow From Investing Activities, Continuing | $-185.09 Million |
Net Cash Flow From Operating Activities, Continuing | $-120.64 Million |
Net Cash Flow From Financing Activities | $305.55 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations After Tax | $-134.38 Million |
Operating Income/Loss | $-145.28 Million |
Basic Average Shares | $54.12 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Nonoperating Income/Loss | $10.91 Million |
Income/Loss From Continuing Operations Before Tax | $-134.38 Million |
Revenues | $0.00 |
Net Income/Loss Attributable To Parent | $-134.38 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Diluted Average Shares | $54.12 Million |
Diluted Earnings Per Share | $2.61 |
Operating Expenses | $145.28 Million |
Other Operating Expenses | $31.67 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-134.38 Million |
Basic Earnings Per Share | $2.61 |
Research and Development | $113.61 Million |
Net Income/Loss | $-134.38 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $368.56 Million |
Other Current Liabilities | $18.22 Million |
Current Assets | $364.13 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity | $289.06 Million |
Liabilities And Equity | $368.56 Million |
Accounts Payable | $4.60 Million |
Wages | $3.64 Million |
Current Liabilities | $26.46 Million |
Noncurrent Assets | $4.43 Million |
Liabilities | $79.50 Million |
Noncurrent Liabilities | $53.04 Million |
Other Non-current Assets | $4.06 Million |
Other Non-current Liabilities | $2.57 Million |
Equity Attributable To Parent | $289.06 Million |
Fixed Assets | $368000.00 |
Long-term Debt | $50.47 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.